Hello, and welcome to this special meeting of stockholders of Imricor Medical Systems, Inc. Please note that today's meeting is being recorded. It is now my pleasure to turn today's meeting over to Steve Wedan. Steve, the floor is yours. Thanks, John. I'd like to welcome everyone to the special meeting of stockholders, Imricor Medical Systems. My name is Steve Wedan, Imricor's Chair and CEO. During the course of today's meeting, our stockholders and their proxies will have the opportunity to ask questions and register votes if you haven't already done so. CDI voters will also have the opportunity to ask questions, but are not entitled to vote at the meeting, except as a proxy for CHESS Depositary Nominees. You can submit your questions at any time during the meeting, as outlined in our meeting guide, and I'll address these questions throughout the meeting. Voting today will be conducted by way of a poll on all items of business, and shortly I will open the voting for all resolutions. Once the voting is open, if you're eligible to vote at this meeting, a polling icon will appear on your screen. Selecting this icon will open a list of resolutions and present you with voting options. To cast your vote, simply click on the appropriate option. Once you select an option, the vote is automatically recorded. You have the ability to change your vote at any time, up until the time I declare voting closed, and I'll provide the meeting with a warning before I do close the voting. Please also note that there are a number of voting exclusions that apply to the resolutions being put to today's meeting, and these have been outlined in the notice of meeting. I now declare the voting open on all items of business. I'd like to take a moment to introduce four of my fellow directors who are also joining us today, Mark Tibbles, Anita Messal, Peter McGregor, and Jeffrey Leighton. Online, we also have our CFO, Jonathon Gut, and Company Secretary, Kobe Li. I've been advised that a quorum is present, and therefore I declare this meeting open and authorized to transact business. Ladies and gentlemen, we'll now turn to the formal business of the meeting. As mentioned previously, you may ask questions online during the meeting via the speech bubble icon that's on your screen. If eligible to vote at the meeting, you may do so up until the time up until I close the voting and click on the by polling by clicking on the polling icon on your screen. If you already sent in your proxy, voting instructions, or voted by internet or telephone before the meeting, your shares have already been voted accordingly. Therefore, stockholders do not need to vote today unless they are voting for the first time or wanna change their previous vote. Voting is currently open for all items of business, and I will provide you with a warning before I move to close voting. Prior to commencement of the meeting, ballot votes have been received, representing approximately 37.15% of Imricor's issued capital, or 93,764,358 shares of Class A common stock. As stated in the proxy statement, I intend to vote all available undirected proxies in favor of all items. Ladies and gentlemen, a copy of the notice of meeting and proxy statement included, including the explanatory memorandum, have been distributed or made available to all stockholders and CDI holders. If you do not have a copy with you, please be reminded that you can download these documents from the ASX website. I propose that these documents be taken as read. As required by the bylaws, a copy of the full register of stockholders is available for viewing at Imricor Medical Systems' place of business in Burnsville and at Imricor Medical Systems' registered address in Melbourne, Australia. You're encouraged to make prior arrangements with either myself in the U.S. or with Kobe Li, Imricor Medical Systems' Company Secretary in Australia, should you like to view the register. We'll now move to the first item of business, ratification and approval of prior issue of shares under the tranche one of the placement. I ask you to consider and if thought fit, to pass this resolution as a separate ordinary resolution. That for the purposes of ASX Listing Rule 7.4, and for all other purposes, the stockholders ratify and approve the prior allotment and issue of 49,514,682 CHESS Depositary Interests, equivalent to 49,514,682 Class A common stock shares. At AUD 0.52 per CDI, under the first tranche of a placement to professional and sophisticated investors, on the terms and conditions in the accompanying explanatory memorandum. Are there any questions in relation to this resolution? Chair, there are no questions at this time. Thanks, Kobe. Prior to the commencement of the meeting, the company received combined direct and proxy votes, as shown on your screen, and I now put the resolution to the meeting and ask you to complete your voting. We'll now move to the next item of business, the approval of the issue of CDIs under tranche two of the placement. I ask you to consider, and if thought fit, to pass this resolution as a separate ordinary resolution. That for the purposes of ASX Listing Rule 7.1, and for all other purposes, approval is given for the company to issue up to 17,550,154 CDIs, equivalent to 17,555,154 shares at AUD 0.52 per CDI to raise up to AUD 9,126.88, under the second tranche of the placement on the terms and conditions in the accompanying explanatory memorandum. Are there any questions in relation to this resolution? Chair, there are no questions at this time. Thanks, Kobe. Prior to the commencement of the meeting, the company received the combined direct and proxy votes, as shown on your screen. I now put the resolution to the meeting and ask you to complete your voting. We'll now move to the next item of business, the approval of the issue of shares under tranche two of the placement. I ask you to consider, and if thought fit, to pass this resolution as a separate ordinary resolution. That for the purposes of ASX Listing Rule 7.1, and for all other purposes, approval is given for the company to issue up to 242,857 shares at an issue price of $0.35 per share to raise up to, in US dollars, $84,999.95 to accredited US investors under the second tranche of the placement, on the terms and conditions in the accompanying explanatory memorandum. Are there any questions in relation to this resolution? Chair, there are no questions at this time. Thanks, Kobe. Prior to the commencement of the meeting, the company received the combined direct and proxy votes, as shown on your screen. I now put the resolution to the meeting and ask you to complete your voting. Ladies and gentlemen, that concludes our items of business. I will shortly close the voting system, so please ensure that you have cast your vote on all resolutions. I'll now pause for 90 seconds to allow you time to finalize those votes. About 30 seconds left. Okay. Thank you, everyone. Voting is now closed. The voting results will be released to the ASX later today. I wanna thank you for taking the time to join the board and me today. Your ongoing support is greatly appreciated, and we look forward to sharing the next phase of Imricor's journey with you all. Thanks again, and have a good day. This concludes the meeting. You may now disconnect.